ProCE Banner Activity

Pharmacotherapy of Schizophrenia

Multimedia

This webcast reviews various pharmacotherapy options for schizophrenia.

Released: February 08, 2021

Share

Faculty

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Provided by

Provided by Postgraduate Institute for Medicine

ProCE Banner

Supporters

This activity is supported by independent educational grants from

Intra Cellular Therapies

Neurocrine Biosciences

Sunovion

Target Audience

This activity is intended for physicians, physician assistants, nurse practitioners, registered nurses, pharmacists and psychologists engaged in the care of patients with schizophrenia.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the latest advances in our understanding of schizophrenia.
  • Implement appropriate strategies to prevent or treat comorbidities that may emerge during treatment for schizophrenia.
  • Develop individualized treatment plans for patients with schizophrenia based on stage of disease and patient responses.

Disclosure

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty Disclosure

Primary Author

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John M. Kane, MD, has disclosed that he has receive consulting fees from Acadia, Alkermes, Allergan, Dainippon Sumitomo, Lundbeck, Intra-Cellular Therapies, Janssen Pharmaceuticals, Johnson & Johnson, LB Pharmaceuticals, Merck, Minerva, Neurocrine Biosciences, Otsuka, Reviva, Roche, Saladax, Sunovion, Takeda, and Teva and has ownership interest in LB Pharmaceuticals.

Disclosure of Unlabeled Use

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

The Global Medical Education planner and manager, Prakash Masand, MD, has disclosed the following

Additional Information

Participation in this self-study activity should be completed in approximately hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 08, 2021, through :

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least % and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.